Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare real-world patient outcomes, lab numbers, and doctor visit tips—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Gut, Labs & Supplements Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Gut, Labs & Supplements Space →
★ Breakthrough Medical Research • 15 Landmark Multi-Trial Guides • 6,280 Indexed Studies

Major Medical Journal Watch (NEJM, Lancet, JAMA, BMJ, Nature Med) (120 Indexed Studies)

Recent publications, longitudinal cohorts, and clinical practice updates from The New England Journal of Medicine, The Lancet, JAMA, BMJ, and Nature Medicine. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.

★ #1 Lead Breakthrough Study • NEJM SURMOUNT-1 (176 Weeks) N = 1,032 Adults • p < 0.001

Once-Weekly Tirzepatide Cuts Type 2 Diabetes Progression by 94% Over 3 Years—With a 22.9% Sustained Weight Reduction

The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).

Two biomedical scientists in white lab coats inside a sunlit medical research laboratory pipetting clinical assay samples and reviewing trial results
Inside the Clinical Evidence Lab: Our research desk audits 6,280 human trials from NEJM, The Lancet, JAMA, and NCBI PubMed—reporting true Absolute Risk Reduction (ARR) and sample sizes (N) without pharma spin.
3. All Indexed Clinical Studies (120)

Major Medical Journal Watch (NEJM, Lancet, JAMA, BMJ, Nature Med) (120)

Page 2 of 4 • Sorted by Participant Sample Size (N)
Journal Watch & Cohort Study NATURE_MED-462142285

Nature Medicine (Longevity & Biotech): A live biotherapeutic product for adult allogeneic hematopoietic cell transplantation recipients: a partially randomized, placebo-controlled phase 1b trial

Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04686-y In a phase 1b study that included an open-label and randomized-controlled cohorts of allogeneic hematopoietic cell transplantation recipients, treatment with the investigationa

Nature Medicine • 2026-11-03 Read Study
Journal Watch & Cohort Study BMJ-3358914835

BMJ Recent Research (Clinical Trials): Malcolm MacCulloch: academic forensic psychiatrist, medical director of Ashworth secure psychiatric hospital, expert witness in the “Yorkshire Ripper” trial, and early researcher on aversion therapy in homosexuality

bmj;395/nov03_9/e100836/F1F1f1Malcolm MacCulloch was a forensic psychiatrist who had a fascinating but at times controversial career, by modern considerations. As a young researcher at Crumpsall Hospital in Manchester he became interested in human sexuality an

BMJ Recent Research • 2026-11-03 Read Study
Journal Watch & Cohort Study BMJ-1334982414

BMJ Recent Research (Clinical Trials): Hassan Burhan: respiratory doctor known for his warmth and humility, who played pivotal role in Liverpool’s covid response

bmj;395/nov03_10/e100837/F1F1f1Hassan Burhan used to do his ward round as a respiratory consultant at Royal Liverpool University Hospital in a necktie and sandals, cracking jokes with patients, cleaners, and hospital porters. Burhan was on first name terms wit

BMJ Recent Research • 2026-11-03 Read Study
Journal Watch & Cohort Study NATURE_MED-2862356220

Nature Medicine (Longevity & Biotech): Regulatable membrane-bound IL-15 engineered TIL cell therapy for immune checkpoint inhibitor-resistant advanced melanoma: pooled analysis of phase 1 and 1/2 trials

Nature Medicine, Published online: 03 November 2026; doi:10.1038/s41591-026-04743-6 As presented at the Society for Immunotherapy of Cancer 2026 Annual Meeting, in a non-prespecified pooled analysis of two trials, amsokigene autoleucel, an autologous tumor-inf

Nature Medicine • 2026-11-03 Read Study
Journal Watch & Cohort Study NATURE_MED-783508082

Nature Medicine (Longevity & Biotech): Global, regional and national burden of cervical cancer in 1990–2023 with forecasts to 2050: a Global Burden of Disease study

Nature Medicine, Published online: 02 November 2026; doi:10.1038/s41591-026-04729-4 Analyses of the Global Burden of Disease study reported 887,000 new cases and 369,000 deaths from cervical cancer worldwide in 2023, which are forecasted to rise by 2050.

Nature Medicine • 2026-11-02 Read Study
Evidence Methodology, PubMed Verification & YMYL Standards

Frequently Asked Questions About dotMD Clinical Trial Breakdowns

Why does dotMD report both Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR) on clinical trials?

Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.

How does dotMD separate human randomized controlled trials (RCTs) from animal or observational studies?

Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.

Why did dotMD replace synthetic "Study Rigor Scores" with primary PubMed PMIDs and trial metadata?

Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.

How do dotMD Research Breakdowns connect to Conditions, Medications, Supplements, and Specialist Doctors?

Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.